All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide

CLDN6/9 (WO2017096163A1 Biosimilar) Recombinant Monoclonal Antibody

Datasheet
Code CSB-RA005508MB4HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
P56747
Target Names
CLDN6/9
Alternative Names
Claudin-6 antibody; Claudin6 antibody; CLD6_HUMAN antibody; CLDN 6 antibody; CLDN6 antibody; OTTHUMP00000159248 antibody; Skullin 2 antibody; Skullin antibody; UNQ757/PRO1488 antibody
Species Reactivity
Human
Immunogen
Recombinant Human CLDN6/9 protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS，pH7.4
Form
Liquid
Troubleshooting and FAQs
Antibody FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
In stock
Description

This recombinant monoclonal antibody is a research-grade biosimilar of the anti-claudin antibodies disclosed in WO2017/096163 A1, targeting CLDN6 and CLDN9 (claudin-6 / claudin-9), two closely related members of the claudin tight-junction protein family. Claudins are tetraspan (four-transmembrane) membrane proteins whose extracellular loops mediate cell–cell interactions that help form tight junction barriers and maintain epithelial polarity. CLDN6 is described as developmentally regulated (oncofetal) and is frequently leveraged as a cell-surface antigen in solid tumor research (e.g., ovarian, endometrial, germ cell tumor contexts), while CLDN9 has also been reported as aberrantly expressed in several cancers (including breast and gastric cancer), making the CLDN6/CLDN9 axis useful for studying tumor-associated tight-junction programs and antigen heterogeneity.

WO2017/096163 A1 describes novel anti-CLDN antibodies and antibody–drug conjugates (ADCs), noting the high extracellular-domain similarity between CLDN6 and CLDN9 and presenting examples of antibodies that are multi-reactive (binding both CLDN6 and CLDN9) as well as antibodies with differing specificity profiles. The patent also reports functional characterization such as cell binding (flow cytometry) and antibody internalization with delivery of a cytotoxic protein payload in cell-based assays, supporting the use of these antibodies for interrogating cell-surface engagement and trafficking. This biosimilar provides the antibody component alone, enabling researchers to study CLDN6/CLDN9 expression profiling, target binding specificity/cross-reactivity, and receptor/antigen internalization mechanisms independent of any conjugated cytotoxic payload effects—useful for early-stage target validation and modality feasibility work (e.g., ADC-relevant internalization behavior) in oncology research models.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Related Products

CLDN6/9 Antibodies

CLDN6/9 Proteins

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Plays a major role in tight junction-specific obliteration of the intercellular space.; (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) entry into hepatic cells.
Gene References into Functions
  1. Antibodies recognizing native CLDN6 as displayed on cell surfaces and mediating complement-dependent cytotoxicity were elicited in vaccinated animals. The data suggest applications of CLDN6 displaying Virus-like particles in cancer immunotherapy. PMID: 29131519
  2. these results suggest that Helicobacter pylori lipopolysaccharide induces TLR2 expression in the gastric adenocarcinoma cells, and that the longer the exposure to lipopolysaccharide, the greater the expression of TLR2 in the cell membrane; consequently the expression of claudin-4, -6, -7 and -9 also increases PMID: 29031421
  3. Study provides evidence that high expression of CLDN6 confers chemoresistance on breast cancer which is mediated by GSTP1, the activity of which is regulated by p53. PMID: 29116019
  4. CLDN6 enhances the chemoresistance to ADM via activating the AF-6/ERK signaling pathway and up-regulating cancer stem cell characters in MDAMB231 cells. PMID: 29159771
  5. we demonstrated that the downregulation of CLDN6 is regulated through promoter methylation by DNMT1, which depends on the SMAD2 pathway, and that CLDN6 is a key regulator in the SMAD2/DNMT1/CLDN6 pathway to inhibit EMT, migration and invasion of breast cancer cells PMID: 28867761
  6. In conclusion, this information from bioinformatics analysis will help future attempts to better understand CLDN6 regulation and functions. PMID: 28656265
  7. high expression of CLDN 6 was observed in approx. 65% of the myxofibrosarcomas, whereas the benign soft tissue tumors did not show a high expression of CLDN 6. The expression of CLDN 6 in the myxofibrosarcomas was significantly higher than those of other tumor specimens. Among the myxofibrosarcomas, the high expression of CLDN 6 was correlated with high FNCLCC grades and high AJCC stages. PMID: 28476380
  8. Results show that DNA methylation down-regulates CLDN6 expression through MeCP2 binding to the CLDN6 promoter, deacetylating H3 and H4, and altering chromatin structure, consequently promoting migratory and invasive phenotype in breast cancer cells. PMID: 27461117
  9. Cldn6 was decreased in alveolar type II-like epithelial cells (A549) and primary small airway epithelial cells when exposed to cigarette smoke ext PMID: 27982694
  10. suggest that claudin-6 induces MMP-2 activation through claudin-1 membrane expression PMID: 27914788
  11. Data show that claudin-6 (CLDN6) R209Q and occludin (OCLN) P24A mutations do not affect HCV pseudoparticles (HCVpp) entry. PMID: 26561856
  12. The expression of ASK1 is correlated with the level of claudin-6 in cervical carcinoma cells and tissues. PMID: 26191261
  13. High levels of CLDN6 are associated with non-small-cell lung cancer. PMID: 24710653
  14. The expression of claudin-6 was down regulated in gastric cancer tissue. PMID: 23919729
  15. Only some hepatitis C virus strains efficiently use CLDN6 for infection. PMID: 23775920
  16. This work provides a proof of concept for the use of Claudin-6 to eliminate residual undifferentiated human pluripotent stem cells from culture. PMID: 23778593
  17. Although claudin-6 and claudin-9 can serve as entry factors in cell lines, hepatitis C virus infection into human hepatocytes is not dependent on claudin-6 and claudin-9. PMID: 23864633
  18. ASK1 signal may play a positive role in the inhibitory effect of claudin-6 in breast cancer. PMID: 22925655
  19. Our results show that claudin-6 protein is significantly down-regulated in breast invasive ductal carcinomas PMID: 22455563
  20. CLDN6 is not a specific biomarker for atypical teratoid rhabdoid tumors as it is expressed in a variety of other pediatric CNS and soft tissue tumors. PMID: 21989342
  21. 17beta-E2 might regulate the expression of claudin-6 and inhibit the proliferation and migration of MCF-7 cells. PMID: 20388399
  22. Increased expression of claudin-6, claudin-7, or claudin-9 is sufficient to enhance tumorigenic properties of a gastric adenocarcinoma cell line. PMID: 20874001
  23. CLDN6 may be a useful positive marker to help further identify atypical teratoid/rhabdoid tumors for diagnostic and treatment purposes PMID: 19220299
  24. Claudins 6, 7, and 9 expressions are closely related to gastric carcinogenesis PMID: 19960275
  25. The up-regulation of claudin-6 expression in MCF-7 breast cancer cells suppresses their malignant phenotypes with a correlation with the restoration of tight junction integrity. PMID: 20367941
  26. claudin-6, downregulates the malignant phenotype of breast carcinoma. PMID: 20215972
  27. Claudin 6 was not found in epithelioid glioblastomas or rhabdoid glioblastomas. PMID: 20118769
  28. CLDN6 and CLDN9, but not CLDN1, are expressed in peripheral blood mononuclear cells, an additional site of HCV replication. PMID: 17804490
  29. claudin-6 and claudin-9 expressed in CD81+ cells also enable the entry of HCV pseudoparticles derived from six of the major genotypes. PMID: 18234789
  30. CLDN6, clustered with CLDN9 at human chromosome 16p13.3, is a four-transmembrane protein with WWCC motif, defined by W-X(17-22)-W-X(2)-C-X(8-10)-C. PMID: 12736707

Show More

Hide All

Subcellular Location
Cell junction, tight junction. Cell membrane; Multi-pass membrane protein.
Protein Families
Claudin family
Tissue Specificity
Expressed in the liver, in peripheral blood mononuclear cells and hepatocarcinoma cell lines.
Database Links

HGNC: 2048

OMIM: 615798

KEGG: hsa:9074

STRING: 9606.ENSP00000328674

UniGene: Hs.533779

Promotions
Reward For Reviews
Free antibody trial
Contact Us

  Email: [email protected]
  Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of email
Email
[email protected]
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Privacy Policy
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*